• Biovex convinced investors to pump in $40M in a Series F for its GM-CSF viral therapy to treat melanoma. Investors included Forbion Capital Partners, Credit Agricole Private Equity, Innoven Partners, New Science Ventures, Triathlon Medical Venture Partners, and Scottish Equity Partners. [Xconomy]

• TargAnox raised $5.1M in a Series A for its oxidative stress programs. The company doesn’t know which diseases it plans to target, yet was able to drag investors Ascent Biomedical Ventures and Partners Innovation Fund for the round. [Xconomy]

• BioAdvance pumped $550,000 into Novira Therapeutics. Novira is involved in the discovery and development of antiviral therapeutics and does not have a lead compound. [BizJournals]

• Australian-based stem cell/regenerative medicine Mesoblast raised $5.58M USD to advance its bone and cartilage products for spinal vertebral disc disease. The programs will be pursued alongside Mesoblast’s ongoing Phase 2 clinical trial in knee osteoarthritis. [ABN Newswire]

• Canada’s Kane Biotech raised $250,000 to further advance its novel, patent-protected biofilms. [MarketWire]

• India’s Cadila Healthcare signed a $300M deal with Eli Lilly to discover and develop drugs to treat cardiovascular diseases. [WSJ]

Image from seekingalpha

Related Posts